Exploiting formyl peptide receptor 2 to promote microglial resolution: a new approach to Alzheimer's disease treatment. (1st May 2021)

• Record Type: Journal Article
• Authors: Wickstead, Edward S.; Irving, Murray A.; Getting, Stephen J.; McArthur, Simon
• Is Part Of: FEBS journal. Volume 289:Number 7(2022)
• Page Start: 1801
• Page End: 1822
• Publication Date: 2021-05-01
• Subjects: Alzheimer's disease -- FPR2 -- microglia -- neuroinflammation -- resolution; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 572
• DOI: 10.1111/febs.15861
• Languages: English
• ISSNs: 1742-464X

Abstract

Abstract : Alzheimer's disease and dementia are among the most significant current healthcare challenges given the rapidly growing elderly population, and the almost total lack of effective therapeutic interventions. Alzheimer's disease pathology has long been considered in terms of accumulation of amyloid beta and hyperphosphorylated tau, but the importance of neuroinflammation in driving disease has taken greater precedence over the last 15–20 years. Inflammatory activation of the primary brain immune cells, the microglia, has been implicated in Alzheimer's pathogenesis through genetic, preclinical, imaging and postmortem human studies, and strategies to regulate microglial activity may hold great promise for disease modification. Neuroinflammation is necessary for defence of the brain against pathogen invasion or damage but is normally self‐limiting due to the engagement of endogenous pro‐resolving circuitry that terminates inflammatory activity, a process that appears to fail in Alzheimer's disease. Here, we discuss the potential for a major regulator and promoter of resolution, the receptor FPR2, to restrain pro‐inflammatory microglial activity, and propose that it may serve as a valuable target for therapeutic investigation in Alzheimer's disease. Abstract : Microglial phenotype can be controlled by activation of the pro‐resolving receptor formylpeptide receptor 2 (FPR2), promoting numerous anti‐inflammatory and protective microglial actions, thereby limiting and delaying neuroinflammatory damage. Targeting of this receptor may hold great potential for therapeutic intervention in Alzheimer's disease. fAβ, fibrillar amyloid beta; ROS, reactive oxygen species.